Evaluation and treatment of the overactive bladder

Gomes, Cristiano Mendes; Trigo-Rocha, Flavio; Arap, Sami; Wein, Alan J.

doi:10.1590/s0041-87812002000100007

Cited by 30 publications

(16 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Rovner et al18 ) , carried out a work on the assessment and treatment of overactive bladder concluding that the results with behavioral therapy are very good, registering a 57% reduction in urge incontinence episodes and a 54% reduction in the amount of urine loss in the elderly. The reduction in incontinence episodes was similar in patients with overactive bladder and incontinence, reduction in the amount of loss was higher in patients with overactive bladder than those with stress urinary incontinence.…”

Section: Discussionmentioning

confidence: 99%

Effects of physiotherapy treatment for urinary incontinence in patient with multiple sclerosis

2017

View full text Add to dashboard Cite

[Purpose] The aim of the study was to evaluate the benefits of physical therapy for urinary incontinence in patients with multiple sclerosis and to verify the impact of urinary incontinence on the patient’s quality of life. [Subject and Methods] A case study of a 55-year-old female patient diagnosed with multiple sclerosis and mixed urinary incontinence was conducted. Physical therapy sessions were conducted once a week, in total 15 sessions, making use of targeted functional electrical vaginal stimulation, along with active exercises for the pelvic floor muscles and electrical stimulation of the posterior tibial nerve, behavioral rehabilitation and exercise at home. [Results] After 15 physical therapy sessions, a patient diagnosed with multiple sclerosis and mixed urinary incontinence showed continued satisfactory results after five months. She showed better quality of life, higher strength of pelvic floor muscle and reduced urinary frequency without nocturia and enuresis. [Conclusion] The physical therapy protocol in this patient with multiple sclerosis and mixed urinary incontinence showed satisfactory results reducing urinary incontinence symptomatology and improving the patient’s quality of life.

show abstract

Section: Discussionmentioning

confidence: 99%

Effects of physiotherapy treatment for urinary incontinence in patient with multiple sclerosis

2017

View full text Add to dashboard Cite

show abstract

“…[1][2][3] It is a chronic condition that significantly impairs the QoL of those affected, 4,5 and ranks among the most prevalent and challenging problems of the lower urinary tract. 5,6 Reports estimate that about one in six adults suffer from OAB. 7,8 The prevalence of OAB increases with age, and is expected to reach 546 million in 2018, worldwide.…”

Section: Introductionmentioning

confidence: 99%

A novel leadless, miniature implantable Tibial Nerve Neuromodulation System for the management of overactive bladder complaints

Heesakkers

Digesu

Breda

et al. 2017

Neurourology and Urodynamics

View full text Add to dashboard Cite

show abstract

“…1–3 Pharmacotherapy with antimuscarinic medications has demonstrated an overall 60% improvement for OAB symptoms. 4 In addition to anticholinergic therapy, the use of intravaginal estrogen to treat atrophy is sporadically used as part of an overall pharmacologic treatment plan.…”

Section: Introductionmentioning

confidence: 99%

Combined Tolterodine and Vaginal Estradiol Cream for Overactive Bladder Symptoms After Randomized Single-Therapy Treatment

Ellington¹,

Szychowski²,

Malek³

et al. 2016

Female Pelvic Med Reconstr Surg

View full text Add to dashboard Cite

Objectives To compare 12 week outcomes of single-therapy tolterodine (Detrol LA ®) extended release to intravaginal estrogen (Estrace ®) for overactive bladder (OAB) symptoms and characterize 24 and 52 week outcomes in women undergoing combined therapy. Methods A single-site randomized, open-label trial in women with urinary frequency, urgency, nocturia, and/or urgency urinary incontinence symptoms was performed. Fifty-eight participants were randomized to oral tolterodine extended release daily or intravaginal estradiol cream nightly for six weeks then twice per week. The primary outcome was change in OAB-questionnaire (OAB-q) symptom bother score at 12 weeks. Secondary outcomes included the health-related quality of life (HRQL) of the OAB-q and a 3-day bladder diary. At 12 weeks, subjects were offered addition of the alternative therapy with follow-up at 24 and 52 weeks. Results There was no difference in symptom bother score improvement between the tolterodine and intravaginal estradiol groups baseline to 12 weeks (20.6±21.7, −15.8±23.3, respectively, p=0.45). There was a significant within group decrease in symptom bother score from baseline to 12 weeks (tolterodine, p < 0.0001, and intravaginal estradiol, p = 0.002). Secondary outcome improvement within groups was noted in the HRQL total, UI episodes and median voiding frequency (all p≤0.03) in the tolterodine group and in the HRQL total score (p=0.03) in the intravaginal estradiol group; with no differences between groups. Combined therapy outcomes at 24 and 52 weeks compared to single therapy at 12 weeks revealed significant improvement in symptom bother score in the intravaginal estradiol +tolterodine group at 24 and 52 weeks (20.0±23.9, p=0.008; −16.7±23.3, p=0.02, respectively) Conclusions Significant within group improvement in OAB-q symptom bother was noted in both the intravaginal estradiol and tolterodine groups for OAB symptoms, with no difference between groups. Greater improvement from 12 week single therapy to 24 and 52 weeks of combined therapy was noted in the group originally assigned to intravaginal estradiol. The role of combined medical therapy for OAB symptoms needs further investigation.

show abstract

Evaluation and treatment of the overactive bladder

Cited by 30 publications

References 60 publications

Effects of physiotherapy treatment for urinary incontinence in patient with multiple sclerosis

Effects of physiotherapy treatment for urinary incontinence in patient with multiple sclerosis

A novel leadless, miniature implantable Tibial Nerve Neuromodulation System for the management of overactive bladder complaints

Combined Tolterodine and Vaginal Estradiol Cream for Overactive Bladder Symptoms After Randomized Single-Therapy Treatment

Contact Info

Product

Resources

About